Member Info for JustHereForHemo

Absolutely! I fire in a few letters and let auto complete do the rest, my 10 year old can speel better than me!

Micky, the important things to bear in mind are that industry have already had opportunity to see efficiency via the use of the humanized mice, there is high confidence that HG-CT-1 will work. We have been told that MD Anderson approached Hemo asking to run the trial because they saw the preclinical test results and were impressed. The risk is safety, a mouse can model the immune system it cannot model every other organ/cell/system in humans so there is a risk of unforeseen side effects ,as per https://clinicaltrials.gov/study/NCT06786533:

Primary outcome: "From the time of HG-CT-1 infusion until Day 28", again From day 1. Its incredibly unlikely we will be spoon fed the minute details, we will get broad strokes, but if there is someone like Bristol Myers Squibb who are interested in investing here? They will be able to get live up to date data.

Just accept we will be the last to know and results will start to be known to company and those with a need to know immediately. We will know if the safety results are acceptable if there is no clinical hold and they move onto patient 2.

Https://shorturl.at/PXKJv

Morning all, Dhub its still NT to buy over 100 shares, MMs have zero interest in letting people buy at present, one would be excused for suspecting there has been some naked shorting going on by them..... Anyway @Marco as many have pointed out the 18 patients 1 month apart is very unlikely, first its expected that the trial will be amended allowing concurrent treatments at some point. But more importantly as Pingu points out, they are testing efficency from the very first patient, they may be calling it phase 1, but its clearly not, its also Phase 2a

WE can, Hemogenxy? Vlad? To the best of my knowledge if they want to use the name "MD Anderson" they have to get approval every time first. IE any RNS with MDA has to go to MDA for signoff, that could take weeks, so honestly? Dont expect Hemo to use the name much, but I am sure they will jump though that hoop occasionally :P

Non standard in the broader scope of clinical trials, in most phase 1 clinical trials the participants are healthy and dont suffer from the target condition and the trial is to assess for safety and side effects with a placebo given to a percentage of the cohort. With treatments like HG-CT-1 the treatment itself is considered toxic, it can kill bone marrow stem cells, it cannot be tested on healthy patients, its also unethical to give someone with AML a placebo so this is not a blind study. As such the patient to receive HG-CT-1 suffers from R/R AML, what the company does not know is what dosage gives the best results in terms of side effects vs efficency, obviously the aim is to cure the patient by delivering only enough HG-CT-1. They can either increase or decrease the dosage if found to be safe/unsafe. If they find complete remission in the first cohort will they increase the dose????? Be interested if Haywain can answer this one.

But to answer the question, 100% yes, this trial encroaches to Phase 2 trials, phase 1 should only be about safety but they need to know the dosage required to treat the patient to determine if that dose level is safe. Which means the likelihood of licensing in Phase 1 is much higher than with other drugs where they dont test for efficacy in phase 1.

Honestly I expect Hemogenyx to turn into a raging torrent pretty damn soon, going clinical with the first injection starts a spark that you cannot hide or deny, its a major milestone that triggers a 30day clock that traders will be all over. When that happens its inevitable that this board will be swamped with the rainbow chasers, the traders etc, we will go from 10 posts a day to 100s or thousands. When that happens I intend to stay away from here as usual, maybe return when it is quiet again if that happens.

Until then genuine LTHers and shareholders are welcome to join the many shareholders on https://www.sharediver.com/ticker/hemo where its USUALLY alot quieter and less spammy and trolly when here gets out of control!

The link, but please dont worry! None of the 06786XXX numbers are live yet, this is just the link early:

https://clinicaltrials.gov/study/NCT06786533

It has been Jam tomorrow for 7 years with the promise of clinical trials within 18months, that 18 months has over run by 5 years and a whole different treatment. But.... its finally here, there is a patient in a bed in a hospital in the US with MD Anderson going to receive an infusion of HG-CT-1.

There has been lots of good news over the years, CBR has had more than most, but nothing close to realizing all important licensing deals on decent value. HG-CT-1 has that potential, it is the Jam tomorrow and whilst we can all appreciate the delays have been HUGE, it is here.

Its not yet visible but should be tomorrow at some point.

A genuine post deserves people spending a bit of time to respond, this is my opinion.

Your timeline? Give or take 1-2 weeks plus or minus I would agree.

RNS's - I actually expect some sort of update to say they are proceeding with the first infusion, be it RNS or interview as it would not demand an RNS, but who knows with vlad. Then yep an RNS for first injection then no update on the trial for atleast 4 weeks. This itself however is very positive, we dont want an update in those 4 weeks, an update in all likelyhood means clinical hold, no news is good news. At which point we can start breathing again as Phase 1 is safety, any safety concerns they would pause the trial so no pause, no update is what we want. At that point we can probably start to expect updates on some efficiency and/or further patients being enrolled and it really should get quite busy.

Funding - Vlad has gone to American brokers to raise funds, at this time we are talking US retail, not institutions, as such he would have raised already but raising in the US has more hurdles than the UK. They are not waiting for results, I am sure if Vlad could raise 2-3m tomorrow from US investors he would as it would allow him to ramp up CBR and CDX. We are talking modest sums in terms of Pharma but big in terms of Hemo, the move to US being an attempt to escape the toxic and stagnant UK raising market where discounts/shorting and flipping are order of the day, VS the US model of buying at market rate but attaching warrants at a premium to encourage growth.

Institutional investment - Honestly dont bet on anything, if there is demand and competition they could license tomorrow if they offered Vlad enough green. Or they could wait for efficiency reports, if so it could be 1-3 patients if the first 3 have very positive reactions to the lowest dose, OR we may not see the desired efficiency until the 2nd or 3rd round of dose escalated treatments meaning 4-6 or 7-9 patients. Based off the results from Senti against FLT3 with a CAR-NK its entirely possible the results at the lowest dosage have significant signs of remission and enough for an institution to make a move.

Pediatrics - Speaking to Haywain and this probably needs an IND, I dont think its waiting for the adult trials or blocked, but progressing in parallel in the background, I heard March or April?

The 7p last Feb came from a significant uptick in visibility caused by FDA approval, it was destroyed by Hemo deciding to go back to Peterhouse to do a placing. Even 7p was a gross undervaluation, but Vlad has accepted he cannot sustain any rise relying on peterhouse specials which is why the US. But likewise Peterhouse traders were part of the pump to rise the SP to allow a placing last year, this year they are not welcome. Is first injection bigger than FDA approval for trials? I think so, the risks are greater now that HG-CT-1 fails, but the potential rewards greater also.

Lets hope for the patient and us Vlad is as good as he says

Seriously..... Someone just had to be Leet.....

And so it begins.

LST - Your last sentence... Vlad has a habit of surprising us.........

Chris, because this is a safety Phase 1 trial, and because failure would be denoted by a clinical hold I cannot imagine they would be able to start the trial and not RNS the first injection. Everything else up to that point and afterwards? Nope, but I am expecting an RNS for first injection.

I think folks are missing the point here, Vlad is under no obligation to release anything beyond essential market sensitive updates. One could argue that he could easily have said nothing about first patient being recruited because the outcome of that was not not a material update. A patient being recruited is no guarantee of them taking part in the trial, either they may be deemed unsuitable or during manufacturing the HG-CT-1 may fail to meet strict requirements. So what? If the first patient is rejected thats a reflection of the first patient NOT Hemogenyx or HG-CT-1, therefore its not a material change and not something that would be required to be communicated. You would hope screening means this wont happen but point remains, do not assume we will hear anything.

HOWEVER. The second that first injection goes into the recruited patient???? EVERYTHING is on the line, the first days and weeks are critical and because of that it IS a material event that requires an RNS.

Bottom line, be thankful we were told they had recruited the first patient, dont expect anything before first injection, Vlad is perfectly at his liberty to update us if he wishes but there is zero requirement to do so.

Id like to see some profits in the next couple of weeks :P

Serious question though would you prefer to be at 1p with 100s of penny stock traders and full expectation of a peterhouse special after next spike, likely first injection..... Or sitting at £4, same mCap with probably < 100 shareholders and confidence that Peterhouse specials are over?

We agree though, Vlad needs to not increase the PR but actually start it, interviews are great for shareholders, but the main audience of those is penny stock traders. He needs to be making Hemogenyx an investable name on a more broader stage, attract investment from pharma investors and not try and win back the traders who jumped ship on consolidation.

LST you can call it wishful thinking but reality is we are in pharma. Licensing deals around CAR-T ARE frequently around 1bn. That's unthinkable to most here because the company is valued at 15m. Would that be unthinkable if HG-CT-1 was owned by Pfizer or Eli? No. What's the difference? As for the recovery, as pants as the SP might still be, it tanked from 400 to 270 on consolidation as more than half of shareholders dumped and shorters piled on. For me being back at 400 with only a fraction of the shareholders is a good sign that we have alot less traders and are set up well for the future.

Nice post Socialist, reminds me of many conversations I have had along similar trains of thought, brings us back to the 2 simple points.

If Hemogenyx today was valued at £500m you could argue thats a fair price, the pipeline would justify it and the mCap would allow the company to raise more than enough thought equity issue to fund research and development.

If Hemogenyx today was valued at £5m you could argue thats a fair price because the risk factor of being unable to raise funds thought equity issue is a massive red flag. That funding issue overarches the science.

With an mCap of 15m and slowly creeping up and the recent fundraise the risk factor is becoming less of an issue which means the science is so much more important today than a week ago. A few million from American investors or getting mCap back north of 50m and suddenly the red flag of funding goes away and your valuations make alot more sense.

Lots of people have sold here recently because they saw the consolidation as a red flag or were penny stock traders, I would say MOST shareholders have sold in the last few months and we have seen not only a consolidation of price but also stock into much fewer hands. A fair few of us who remain share your ambitions for the targets below and as much as the remaining penny stock traders may laugh the reality is your valuations ARE achievable, the irony is the low SP is what justifies a low SP, but likewise as the SP creeps up (It IS creeping up) each inch reduces the risk slightly, increases headroom and makes a higher target more achievable. The shorters and trolls accurately identified the risks here, it was never the science it was always the low mCap and SP, the lower it was the higher the risk. With another few 100k banked the risk for now is negligible and the chances of significant news never been higher.

The UK market is dire, little liquidity so placings are done at the mercy of the placees who demand a large discount, short sell and dump PRE price fix (Yes illegally, yes it 100% happens). Then dump when they get the shares or close out shorts. Vs the US model where investors take larger stakes, demand warrants and want to hold and push the SP up to make money on the warrants. That increases valuations, improves liquidity and the shareholders can expand their portfolio without flipping asap.

Was there criminality/manipulation and underhand dealings here?

YES! Zero doubt, but neither I nor I suspect Vlad or anyone else want to waste time and energy pursuing it if we can move forward. The book of traders available to Peterhouse cannot be trusted, simple as that, so they are gone from placings, the penny stock traders have all but vanished, the low volume is something that should be welcomed.

My efforts are multiple:

Engaged with company over the years to try and get them to stop using peterhouse for specials, this appears to have worked.

Engaged with a very large news outlet to cover Hemo + the London markets, this is ongoing, had a 1hr call with reporter last week, its progressing but slow.

Engaged with the FCA - They have given me information I didnt know but as to the state of ongoing investigations? They wont provide updates. I dont have much faith in them TBH.

Anyway, I am not a passive investor, I dont just sit back and trust the company to make the best decisions, nor do I accept that traders can say what and have no impact on a stock.

All that said? I am extremely positive about whats coming in the near future and I look forward to the first injection.

I think you missed my point LST, no reason whatsoever to assume placee will or will not sell shares at any given date at any point in the future. It just so happens to suit the narrative of those trading to implant and amplify the argument that Wednesday is somehow significant. Its not. We have both been here for years, I would much prefer the SP to move UP ^ though which means attracting new investors and focusing on the positives.